Tag Archives: William Tanner

Supernus Pharmaceuticals (SUPN) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Supernus Pharmaceuticals (NASDAQ: SUPN) yesterday and set a price target of $56. The company’s shares closed yesterday at $48.85. Tanner noted: “: We reiterate our Overweight rating and $56 PT

What Made Cantor Fitzgerald Downgrade Vital Therapies’ Stock?

Cantor Fitzgerald analyst William Tanner downgraded Vital Therapies (NASDAQ: VTL) to Hold today and set a price target of $0.50. The company’s shares closed yesterday at $6.30. Tanner commented: “: We are downgrading our rating on VTL shares from and

Cantor Fitzgerald Reiterates Their Buy Rating on Vital Therapies (VTL)

In a report released yesterday, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Vital Therapies (NASDAQ: VTL), with a price target of $18. The company’s shares closed on Friday at $6.68. Tanner said: “: We reiterate the Overweight

Acorda Therapeutics (ACOR) Initiated with a Hold at Cantor Fitzgerald

In a report released today, William Tanner from Cantor Fitzgerald initiated coverage with a Hold rating on Acorda Therapeutics (NASDAQ: ACOR) and a price target of $32. The company’s shares closed yesterday at $29.15. According to TipRanks.com, Tanner is a

Cantor Fitzgerald Initiates a Buy Rating on Vital Therapies (VTL)

Cantor Fitzgerald analyst William Tanner initiated coverage with a Buy rating on Vital Therapies (NASDAQ: VTL) today and set a price target of $18. The company’s shares opened today at $8.95, close to its 52-week high of $9.75. Tanner noted:

TherapeuticsMD (TXMD) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $27. The company’s shares opened today at $5.25. Tanner said: “: We reiterate the Overweight rating and raise our